RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer

Cell Death and Disease

Volumn 5, Issue 10, 2014, Pages

  Kang, R ^a   Hou, W ^a   Zhang, Q ^a   Chen, R ^a   Lee, Y J ^a   Bartlett, D L ^a   Lotze, M T ^a   Tang, D ^a   Zeh, H J ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR; KRAS PROTEIN, HUMAN; KRAS2 PROTEIN, MOUSE; ONCOPROTEIN; PROTEIN P21; RAS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CELL DEATH; CONTROLLED STUDY; DOWN REGULATION; HYPOXIA; IN VITRO STUDY; MOUSE; NONHUMAN; ONCOGENE K RAS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR GROWTH; ANIMAL; AUTOPHAGY; BIOLOGICAL MODEL; C57BL MOUSE; CELL HYPOXIA; CELL SURVIVAL; HUMAN; METABOLISM; ONCOGENE; PANCREAS TUMOR; PATHOLOGY; PROTEIN STABILITY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSGENIC MOUSE; TUMOR CELL LINE;

MUS;

ANIMALS; AUTOPHAGY; CELL HYPOXIA; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, BIOLOGICAL; NF-KAPPA B; ONCOGENES; PANCREATIC NEOPLASMS; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

EID: 84923123479     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.445     Document Type: Article

References (57)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Stan SD, Singh SV, Brand RE. Chemoprevention strategies for pancreatic cancer. Nat Rev Gastroenterol Hepatol 2010; 7: 347-356.
3. Wang Z, Li Y, Ahmad A, Banerjee S, Azmi AS, Kong D et al. Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol 2011; 8: 27-33.
4. Bryant KL, Mancias JD, Kimmelman AC, Der CJ. KRAS: feeding pancreatic cancer proliferation. Trends Biochem Sci 2014; 39: 91-100.
5. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011; 11: 761-774.
6. di Magliano MP, Logsdon CD. Roles for KRAS in pancreatic tumor development and progression. Gastroenterology 2013; 144: 1220-1229.
7. Stephen AG, Esposito D, Bagni RK, McCormick F. Dragging ras back in the ring. Cancer Cell 2014; 25: 272-281.
8. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 2008; 8: 705-713.
9. Chang Q, Jurisica I, Do T, Hedley DW. Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer. Cancer Res 2011; 71: 3110-3120.
10. Kizaka-Kondoh S, Itasaka S, Zeng L, Tanaka S, Zhao T, Takahashi Y et al. Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer. Clin Cancer Res 2009; 15: 3433-3441.
11. Spivak-Kroizman TR, Hostetter G, Posner R, Aziz M, Hu C, Demeure MJ et al. Hypoxia triggers Hedgehog-mediated tumor stromal interactions in pancreatic cancer. Cancer Res 2013; 73: 3235-3247.
12. Guillaumond F, Leca J, Olivares O, Lavaut MN, Vidal N, Berthezene P et al. Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Proc Natl Acad Sci USA 2013; 110: 3919-3924.
13. Chang Q, Jurisica I, Do T, Hedley DW. Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer. Cancer Res 2011; 71: 3110-3120.
14. Kwon SJ, Song JJ, Lee YJ. Signal pathway of hypoxia-inducible factor-1alpha phosphorylation and its interaction with von Hippel-Lindau tumor suppressor protein during ischemia in MiaPaCa-2 pancreatic cancer cells. Clin Cancer Res 2005; 11: 7607-7613.
15. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732.
16. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010; 28: 367-388.
17. Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J et al. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med 2009; 7: 17.
18. Vernon PJ, Loux TJ, Schapiro NE, Kang R, Muthuswamy R, Kalinski P et al. The receptor for advanced glycation end products promotes pancreatic carcinogenesis and accumulation of myeloid-derived suppressor cells. J Immunol 2013; 190: 1372-1379.
19. Kang R, Loux T, Tang D, Schapiro NE, Vernon P, Livesey KM et al. The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia. Proc Natl Acad Sci USA 2012; 109: 7031-7036.
20. Kang R, Tang D, Livesey KM, Schapiro NE, Lotze MT, Zeh HJ 3rd. The Receptor for Advanced Glycation End-products (RAGE) protects pancreatic tumor cells against oxidative injury. Antioxid Redox Signal 2011; 15: 2175-2184.
21. Kang R, Tang D, Schapiro NE, Livesey KM, Farkas A, Loughran P et al. The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ 2010; 17: 666-676.
22. Kang R, Tang D, Schapiro NE, Loux T, Livesey KM, Billiar TR et al. The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics. Oncogene 2014; 33: 567-577.
23. Kang R, Tang D, Lotze MT, Zeh HJ 3rd. AGER/RAGE-mediated autophagy promotes pancreatic tumorigenesis and bioenergetics through the IL6-pSTAT3 pathway. Autophagy 2012; 8: 989-991.
24. Kang R, Tang D, Lotze MT, Zeh HJ 3rd. RAGE regulates autophagy and apoptosis following oxidative injury. Autophagy 2011; 7: 442-444.
25. Kang R, Tang D, Loze MT, Zeh HJ. Apoptosis to autophagy switch triggered by the MHC class III-encoded receptor for advanced glycation endproducts (RAGE). Autophagy 2011; 7: 91-93.
26. Vengellur A, LaPres JJ. The role of hypoxia inducible factor 1alpha in cobalt chloride induced cell death in mouse embryonic fibroblasts. Toxicol Sci 2004; 82: 638-646.
27. Dai ZJ, Gao J, Ma XB, Yan K, Liu XX, Kang HF et al. Up-regulation of hypoxia inducible factor-1alpha by cobalt chloride correlates with proliferation and apoptosis in PC-2 cells. J Exp Clin Cancer Res 2012; 31: 28.
28. Pichiule P, Chavez JC, Schmidt AM, Vannucci SJ. Hypoxia-inducible factor-1 mediates neuronal expression of the receptor for advanced glycation end products following hypoxia/ ischemia. J Biol Chem 2007; 282: 36330-36340.
29. Tafani M, Schito L, Pellegrini L, Villanova L, Marfe G, Anwar T et al. Hypoxia-increased RAGE and P2X7R expression regulates tumor cell invasion through phosphorylation of Erk1/2 and Akt and nuclear translocation of NF-{kappa}B. Carcinogenesis 2011; 32: 1167-1175.
30. Akakura N, Kobayashi M, Horiuchi I, Suzuki A, Wang J, Chen J et al. Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 2001; 61: 6548-6554.
31. Yokoi K, Fidler IJ. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin Cancer Res 2004; 10: 2299-2306.
32. Greijer AE, van der Wall E. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 2004; 57: 1009-1014.
33. Zhang H, Bosch-Marce M, Shimoda LA, Tan YS, Baek JH, Wesley JB et al. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem 2008; 283: 10892-10903.
34. Bellot G, Garcia-Medina R, Gounon P, Chiche J, Roux D, Pouyssegur J et al. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol Cell Biol 2009; 29: 2570-2581.
35. Rausch V, Liu L, Apel A, Rettig T, Gladkich J, Labsch S et al. Autophagy mediates survival of pancreatic tumour-initiating cells in a hypoxic microenvironment. J Pathol 2012; 227: 325-335.
36. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8: 445-544.
37. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003; 4: 437-450.
38. Kikuchi H, Pino MS, Zeng M, Shirasawa S, Chung DC. Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer. Cancer Res 2009; 69: 8499-8506.
39. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2: 301-310.
40. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V et al. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 2008; 453: 807-811.
41. van Uden P, Kenneth NS, Rocha S. Regulation of hypoxia-inducible factor-1alpha by NF-kappaB. Biochem J 2008; 412: 477-484.
42. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W et al. Blockade of RAGEamphoterin signalling suppresses tumour growth and metastases. Nature 2000; 405: 354-360.
43. Gebhardt C, Riehl A, Durchdewald M, Nemeth J, Furstenberger G, Muller-Decker K et al. RAGE signaling sustains inflammation and promotes tumor development. J Exp Med 2008; 205: 275-285.
44. Heijmans J, Buller NV, Hoff E, Dihal AA, van der Poll T, van Zoelen MA et al. Rage signaling promotes intestinal tumourigenesis. Oncogene 2012; 32: 1202-1206.
45. DiNorcia J, Lee MK, Moroziewicz DN, Winner M, Suman P, Bao F et al. RAGE gene deletion inhibits the development and progression of ductal neoplasia and prolongs survival in a murine model of pancreatic cancer. J Gastrointest Surg 2012; 16: 104-112 discussion 112.
46. Tateno T, Ueno S, Hiwatashi K, Matsumoto M, Okumura H, Setoyama T et al. Expression of receptor for advanced glycation end products (RAGE) is related to prognosis in patients with esophageal squamous cell carcinoma. Ann Surg Oncol 2009; 16: 440-446.
47. Landesberg R, Woo V, Huang L, Cozin M, Lu Y, Bailey C et al. The expression of the receptor for glycation endproducts (RAGE) in oral squamous cell carcinomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 105: 617-624.
48. Bartling B, Demling N, Silber RE, Simm A. Proliferative stimulus of lung fibroblasts on lung cancer cells is impaired by the receptor for advanced glycation end-products. Am J Respir Cell Mol Biol 2006; 34: 83-91.
49. Takeuchi A, Yamamoto Y, Tsuneyama K, Cheng C, Yonekura H, Watanabe T et al. Endogenous secretory receptor for advanced glycation endproducts as a novel prognostic marker in chondrosarcoma. Cancer 2007; 109: 2532-2540.
50. Riuzzi F, Sorci G, Donato R. RAGE expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumor growth. Am J Pathol 2007; 171: 947-961.
51. Chun SY, Johnson C, Washburn JG, Cruz-Correa MR, Dang DT, Dang LH. Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1alpha and HIF-2alpha target genes. Mol Cancer 2010; 9: 293.
52. White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer 2012; 12: 401-410.
53. Kang R, Tang D. Autophagy in pancreatic cancer pathogenesis and treatment. Am J Cancer Res 2012; 2: 383-396.
54. Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev 2011; 25: 717-729.
55. Rosenfeldt MT, O'Prey J, Morton JP, Nixon C, MacKay G, Mrowinska A et al. p53 status determines the role of autophagy in pancreatic tumour development. Nature 2013; 504: 296-300.
56. Yang A, Rajeshkumar NV, Wang X, Yabuuchi S, Alexander BM, Chu GC et al. Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations. Cancer Discov 2014; 4: 905-913.
57. Liliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, Hofer S et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004; 113: 1641-1650.